Federico E. Rey

Federico E. Rey

Auto-generated profile, based on publicly available information

Federico E. Rey

Department of Bacteriology, University of Wisconsin-Madison, Madison, WI, USA.

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NVNicholas M. Vogt
Nicholas M. Vogt
RKRobert L. Kerby
Robert L. Kerby
KDKimberly A. Dill-McFarland
Kimberly A. Dill-McFarland
SHSandra J. Harding
Sandra J. Harding
AMAndrew P. Merluzzi
Andrew P. Merluzzi
FRFederico E. Rey
Federico E. Rey
Alzheimer’s disease (AD) is the most common form of dementia. However, the etiopathogenesis of this devastating disease is not fully understood. Recent studies in rodents suggest that alterations in the gut microbiome may contribute to amyloid deposition, yet the microbial communities associated with AD have not been characterized in humans. Towards this end, we characterized the bacterial taxonomic composition of fecal samples from participants with and without a diagnosis of dementia due to AD. Our analyses revealed that the gut microbiome of AD participants has decreased microbial diversity and is compositionally distinct from control age- and sex-matched individuals. We identified phylum- through genus-wide differences in bacterial abundance including decreased Firmicutes, increased Bacteroidetes, and decreased Bifidobacterium in the microbiome of AD participants. Furthermore, we observed correlations between levels of differentially abundant genera and cerebrospinal fluid (CSF) biomarkers of AD. These findings add AD to the growing list of diseases associated with gut microbial alterations, as well as suggest that gut bacterial communities may be a target for therapeutic intervention.

1 May 2015 in mBio
Verified
Journal Article
Open access
PDF file
KRKymberleigh A. Romano
Kymberleigh A. Romano
EVEugenio I. Vivas
Eugenio I. Vivas
DADaniel Amador-Noguez
Daniel Amador-Noguez
FRFederico E. Rey
Federico E. Rey
Choline is a water-soluble nutrient essential for human life. Gut microbial metabolism of choline results in the production of trimethylamine (TMA), which upon absorption by the host is converted in the liver to trimethylamine-N-oxide (TMAO). Recent studies revealed that TMAO exacerbates atherosclerosis in mice and positively correlates with the severity of this disease in humans. However, which microbes contribute to TMA production in the human gut, the extent to which host factors (e.g., genotype) and diet affect TMA production and colonization of these microbes, and the effects TMA-producing microbes have on the bioavailability of dietary choline remain largely unknown. We screened a collection of 79 sequenced human intestinal isolates encompassing the major phyla found in the human gut and identified nine strains capable of producing TMA from cholinein vitro. Gnotobiotic mouse studies showed that TMAO accumulates in the serum of animals colonized with TMA-producing species, but not in the serum of animals colonized with intestinal isolates that do not generate TMA from cholinein vitro. Remarkably, low levels of colonization by TMA-producing bacteria significantly reduced choline levels available to the host. This effect was more pronounced as the abundance of TMA-producing bacteria increased. Our findings provide a framework for designing strategies aimed at changing the representation or activity of TMA-producing bacteria in the human gut and suggest that the TMA-producing status of the gut microbiota should be considered when making recommendations about choline intake requirements for humans.IMPORTANCECardiovascular disease (CVD) is the leading cause of death and disability worldwide, and increased trimethylamineN-oxide (TMAO) levels have been causally linked with CVD development. This work identifies members of the human gut microbiota responsible for both the accumulation of trimethylamine (TMA), the precursor of the proatherogenic compound TMAO, and subsequent decreased choline bioavailability to the host. Understanding how to manipulate the representation and function of choline-consuming, TMA-producing species in the intestinal microbiota could potentially lead to novel means for preventing or treating atherosclerosis and choline deficiency-associated diseases.

1 December 2016 in Molecular Cell
Verified
Journal Article
Closed access
KKKimberly A. Krautkramer
Kimberly A. Krautkramer
JKJulia H. Kreznar
Julia H. Kreznar
KRKymberleigh A. Romano
Kymberleigh A. Romano
EVEugenio I. Vivas
Eugenio I. Vivas
GBGregory A. Barrett-Wilt
Gregory A. Barrett-Wilt
JDJohn M. Denu
John M. Denu

5 November 2018 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
KKKazuyuki Kasahara
Kazuyuki Kasahara
KKKimberly A. Krautkramer
Kimberly A. Krautkramer
EOElin Org
Elin Org
KRKymberleigh A. Romano
Kymberleigh A. Romano
RKRobert L. Kerby
Robert L. Kerby
FRFederico E. Rey
Federico E. Rey

22 December 2018 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
NVNicholas M. Vogt
Nicholas M. Vogt
KRKymberleigh A. Romano
Kymberleigh A. Romano
BDBurcu F. Darst
Burcu F. Darst
CECorinne D Engelman
Corinne D Engelman
SJSterling C. Johnson
Sterling C. Johnson
FRFederico E. Rey
Federico E. Rey
Trimethylamine N-oxide (TMAO), a small molecule produced by the metaorganismal metabolism of dietary choline, has been implicated in human disease pathogenesis, including known risk factors for Alzheimer’s disease (AD), such as metabolic, cardiovascular, and cerebrovascular disease. In this study, we tested whether TMAO is linked to AD by examining TMAO levels in cerebrospinal fluid (CSF) collected from a large sample (n = 410) of individuals with Alzheimer’s clinical syndrome (n = 40), individuals with mild cognitive impairment (MCI) (n = 35), and cognitively-unimpaired individuals (n = 335). Linear regression analyses were used to determine differences in CSF TMAO between groups (controlling for age, sex, and APOE ε4 genotype), as well as to determine relationships between CSF TMAO and CSF biomarkers of AD (phosphorylated tau and beta-amyloid) and neuronal degeneration (total tau, neurogranin, and neurofilament light chain protein). CSF TMAO is higher in individuals with MCI and AD dementia compared to cognitively-unimpaired individuals, and elevated CSF TMAO is associated with biomarkers of AD pathology (phosphorylated tau and phosphorylated tau/Aβ42) and neuronal degeneration (total tau and neurofilament light chain protein). These findings provide additional insight into gut microbial involvement in AD and add to the growing understanding of the gut–brain axis.

4 June 2023 in Cell Host & Microbe
Verified
Journal Article
Open access
KKKazuyuki Kasahara
Kazuyuki Kasahara
RKRobert L. Kerby
Robert L. Kerby
QZQijun Zhang
Qijun Zhang
MPMeenakshi Pradhan
Meenakshi Pradhan
MMMargarete Mehrabian
Margarete Mehrabian
FRFederico E. Rey
Federico E. Rey
The microbes and microbial pathways that influence host inflammatory disease progression remain largely undefined. Here, we show that variation in atherosclerosis burden is partially driven by gut microbiota and is associated with circulating levels of uric acid (UA) in mice and humans. We identify gut bacterial taxa spanning multiple phyla, including Bacillota, Fusobacteriota, and Pseudomonadota, that use multiple purines, including UA as carbon and energy sources anaerobically. We identify a gene cluster that encodes key steps of anaerobic purine degradation and that is widely distributed among gut-dwelling bacteria. Furthermore, we show that colonization of gnotobiotic mice with purine-degrading bacteria modulates levels of UA and other purines in the gut and systemically. Thus, gut microbes are important drivers of host global purine homeostasis and serum UA levels, and gut bacterial catabolism of purines may represent a mechanism by which gut bacteria influence health.